Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer
Status:
Terminated
Trial end date:
2016-08-02
Target enrollment:
Participant gender:
Summary
This neoadjuvant chemotherapy protocol focusing on "triple-negative" breast cancers alone
will gather a foundation of primary tumor and axillary lymph nodal response to primary
chemotherapy and ongoing correlated disease-free (DFS) and overall survival (OS) outcome
data. This comparative data can then be used in building subsequent trials.